MDGL250117C160000
- 148.90
- 0.000.00%
Madrigal Pharmaceuticals Newsroom
Goldman Sachs Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $530
Evercore Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $392
Piper Sandler Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $336
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Sell Rating, Maintains Target Price $154
Bank of America Securities Reaffirms Their Sell Rating on Madrigal Pharmaceuticals (MDGL)
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN), Beam Therapeutics (BEAM) and Madrigal Pharmaceuticals (MDGL)
Jefferies Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $398
A Quick Look at Today's Ratings for Madrigal Pharmaceuticals(MDGL.US), With a Forecast Between $154 to $427
Madrigal Pharmaceuticals Price Target Raised to $400.00/Share From $390.00 by HC Wainwright & Co.
Madrigal Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Madrigal Pharmaceuticals Analyst Ratings
Positive Outlook and Buy Rating for Madrigal Pharmaceuticals Driven by Strong Rezdiffra Performance and Financial Stability
Madrigal Pharmaceuticals Analyst Ratings
Madrigal Pharmaceuticals' Rezdiffra Shows Strong Market Growth and Positive Outlook, Justifying Buy Rating
JMP Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $427
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Sell Rating, Announces Target Price $155
Leerink Partners Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Madrigal Pharmaceuticals (MDGL)
Oppenheimer Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $400
Madrigal Pharmaceuticals Analyst Ratings